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ABSTRACT
It is generally assumed that transposable elements,
including endogenous retroviruses (ERVs), are
silenced by DNA methylation/chromatin structure
in mammalian cells. However, there have been very
few experimental studies to examine the methyla-
tion status of human ERVs. In this study, we
determined and compared the methylation status
of the 50 long terminal repeats (LTRs) of different
copies of the human endogenous retrovirus (HERV)
family HERV-E, which are inserted in various
genomic contexts. We found that three HERV-E
LTRs which function as alternative gene promoters
in placenta are unmethylated in that tissue but
heavily methylated in blood cells, where these LTRs
are not active promoters. This difference is not
solely due to global hypomethylation in placenta,
since two general measures of methylation levels of
HERV-E and HERV-K LTRs suggest only 10–15%
lower overall HERV methylation in placenta com-
pared to blood. Comparisons between methylation
levels of the LTR-derived gene promoters and six
random HERV-E LTRs in placenta showed that the
former display significantly lower methylation levels
than random LTRs. Moreover, the differences in
methylation between LTRs cannot always be
explained by their genomic environment, since
methylation of flanking sequences can be very
different from methylation of the LTR itself.
INTRODUCTION
Methylation of cytosines is one of the marks of
transcriptionally inactive chromatin (1). Constitutively
silenced chromatin, like pericentromeric heterochromatin,
is heavily methylated in all cells throughout an organism’s
lifespan, whereas most promoters of genes are methylated
only when permanent silencing is needed during develop-
ment (2). Clearly, diﬀerent loci in the genome are treated
distinctly by the DNA methylation machinery and more
generally by the heterochromatin assembly pathway.
To what extent those diﬀerences are mediated by
diﬀerences in composition of the DNA sequence, the
genomic context or by DNA binding proteins remains
generally unclear.
One class of sequences illustrating the complexities of
methylation patterns is comprised of transposable ele-
ments (TEs). TEs are thought to be silenced by heavy CpG
methylation in mammalian genomes (3). However, a
number of reports suggest that the silencing of repeated
sequences is not homogeneous throughout the genome or
in all cells of an organism. For example, the human
endogenous retrovirus (HERV) family HERV-K displays
diﬀerent methylation levels between copies and between
cell lines (4). In Brassica napus, diﬀerences in methylation
are also observed between random selected copies of S1, a
SINE element (5). In humans, the promoter region of
ERVWE1, a HERV-W copy encoding Syncytin-1 is
speciﬁcally hypomethylated in placenta and methylated
in other tissues (6). Syncytin-1 is a retroviral protein with
fusogenic properties involved in the development of
human placenta (7). However, it is unknown whether
hypomethylation in this tissue is a characteristic speciﬁc to
this co-opted copy or general to the HERV-W family. It is
notable that DNA methylation, and the heterochromatic
structure in general, have the property of spreading from
the silenced target to the surrounding DNA (5,8,9). Such
observations have led to the assumption that transposable
elements should generally have the same methylation level
as their ﬂanking sequence (10). If this is true, diﬀerent
methylation levels between endogenous retroviral copies
should reﬂect the methylation status of the surrounding
DNA. This assumption, however, has not been extensively
tested.
Placenta is of particular interest with respect to
expression of endogenous retroviruses (ERVs) because
many ERV families are transcribed in this tissue (11–16).
One of the hypotheses proposed to explain this relatively
high degree of ERV expression is that placenta has lower
DNA methylation compared to other tissues (13,17).
Indeed, in mouse blastocysts, the trophectoderm seems to
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human blastocysts the opposite situation has been
reported (19). On the other hand, human term placentas
show about 20% lower overall DNA methylation
compared to brain, liver and peripheral blood lympho-
cytes (PBL) (20,21) and 10–27% lower methylation of
Alu retroelements compared to that observed in spleen
(22). Moreover, compared to other tissues, placenta has a
higher frequency of HERV copies acting as alternative
promoters to cellular genes (23,24). These gene promoters
of retroviral origin initiate transcription in their long
terminal repeat (LTR) and, in most cases; their activity is
tissue-speciﬁc. Indeed, about 40% of the tissue-speciﬁc
LTR-derived gene promoters which have been docu-
mented are active in placenta. This could be the result of
the general hypomethylation of this tissue allowing the
expression of many HERV copies and consequently of
LTR-derived promoters as well. The main questions
addressed in this study were (i) whether the methylation
level of LTR-derived gene promoters is representative
of the general methylation of HERVs in placenta and
(ii) whether diﬀerences in methylation between copies can
be explained by diﬀering genomic environments. To
answer to these questions, we analyzed the methylation
status of three HERV-E LTRs active as alternative gene
promoters and of six other highly related LTRs in
diﬀerent genomic contexts.
MATERIALS AND METHODS
Samples
Two term placenta samples were used for all bisulﬁte
sequencing and combined bisulﬁte and restriction enzyme
analysis (COBRA) experiments: P24 from a pre-eclamptic
pregnancy, gestational age 32 weeks and P25, from a
normal placenta, gestational age 40 weeks. For LTR-
Mid1 only, two additional placental samples were used:
P15 from an eclamptic pregnancy, gestational age 38
weeks and P33, from a pre-eclamptic pregnancy, gesta-
tional age 40 weeks. P21, a normal term placenta sample,
gestational age 41 weeks, was used for the Southern blot.
Diﬀerent samples of normal PBLs were used for bisulﬁte
methods (sequencing and COBRA) and Southern
blotting.
COBRAand Bisulfite sequencing
Bisulﬁte conversion of DNA was performed using the EZ
DNA methylation kit (Zymo Research), according to the
manufacturer’s protocol, with the following modiﬁcation:
genomic DNA was incubated with CT conversion reagent
at 508C for a total of nearly 4h with 15s pulses to 958C
every 15min. Converted DNA was eluted in 20ml elution
buﬀer and 2ml was used for PCR. All primers used are
shown in Supplementary Table S1. To ensure that only the
LTR of interest was ampliﬁed, the forward primer was
located in the 50 ﬂanking sequence of this LTR. A ﬁrst
PCR (PCR1) was performed under the following condi-
tions: 948C for 5min, followed by 40 cycles of 948C for
30s, variable annealing temperatures depending on the
primers for 1min, and 728C for 30s. A ﬁnal elongation
step of 10min was included in all reactions. In most cases,
a second PCR (PCR2) was necessary to obtain enough
PCR products for subsequent analysis. PCR2 was
performed either by using the same primers as for PCR1
or with nested primers (Table S1). For PCR2, 2ml of the
PCR1 product was used as template. PCR2 conditions
were the same as for PCR1 except that only 35 cycles were
performed. PCR1 and PCR2 were performed on each
sample in three independent reactions to control for
PCR bias in the following COBRA. The products
were analyzed by gel electrophoresis and puriﬁed
with MiniElute (Qiagen), then digested individually with
restriction enzymes which contain CpG dinucleotides in
their recognition sites. If the CpG was methylated in the
original sample, then the restriction enzyme site is
maintained during bisulﬁte treatment and the PCR
product will be digested. Enzymes used and the number
of restriction sites in each LTR is given in Supplementary
Table S2. In some cases, several CpG sites were tested by a
single restriction enzyme (e.g. four CpG sites of LTR-EBR
were tested by TaqI, see Table S2). In these situations, it is
impossible to distinguish among methylation states of the
diﬀerent CpGs. Therefore, the same results of COBRA are
indicated for all those CpGs in Figures 2 and 5 and they
are marked by a connector line. Consequently, COBRA
results when connected should be regarded as a sum of
several CpG sites and not separately for each CpG site.
All enzymes were purchased from New England Biolabs,
and digests were performed following manufacturer’s
instructions. No PCR bias was observed between diﬀerent
PCRs performed on the same sample. Hence, the three
PCR products from the same individual sample were
pooled and cloned using the pGEM-T Easy kit (Promega).
Sequencing was performed by McGill University and
Genome Que ´ bec Innovation Centre Sequencing Platform.
Only unique sequences (as determined by either unique
CpG methylation pattern or unique non-conversion of
non-CpG cytosines) are shown, and all sequences had a
conversion rate496%.
Genome-wide COBRA ofHERVE-LTRs
To compare the methylation of HERV-E LTRs
between placenta and PBL in a genome-wide way, the
LTR2B-cons-fw: 50-TGAGGGAAGAGAGAGATTTTT
30 and the LTR2B-cons- rev: 50- ATTATAAAAAAAAA
AACTTTATTCAACTAA-30 primers were chosen in a
well-conserved region of the LTR2B consensus given by
Repbase (25). (LTR2B is the Repbase nomenclature for a
major subfamily of HERV-E LTRs to which LTR-MID1
and LTR-PTN belong). An in silico PCR was performed
with the UCSC In-silico PCR program (UCSC Genome
Browser) using as primer sequences the corresponding
LTR2B-cons-fw and -rv sequences for non-bisulﬁte
converted DNA. Seventy-eight HERV-E LTRs were
predicted to be ampliﬁed. A multiple alignment of the
78 sequences showed presence of a SnaBI restriction
site (TACGTA) in 42 sequences, a ClaI (ATCGAT) in
36 sequences and a DraI (TTTAAA) in all 78 sequences
(two sites present in most of them and at least one was
maintained). For band intensity quantiﬁcation the
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used. To deduce the percent of methylated CpGs, the
theoretical number of CpG-carrying sequences out of the
total of ampliﬁed sequences as predicted by the In-silico
PCR was used.
Methylation sensitive Southern blot
Genomic DNA from placenta (sample P21) and PBL was
digested with the methylation sensitive enzyme (HpaII)
and the methylation insensitive isoschisomer (MspI)
overnight. Then, the ApoI restriction enzyme was added
for 5h. All digestions were performed according to the
manufacturer’s instructions (New England Biolabs).
Digested DNA was separated in a 1% agarose gel
and transferred to a Zeta-Probe GT Blotting Membrane
(Bio-Rad). The probe corresponding to the gag region
of HERV-K was ampliﬁed by PCR with probe-K-fw:
AGCGTGGTCATTGAGGACA and probe-K-rev:
AAAGCTGAGATAAGAGGCATATTT primers. The
150bp long PCR product was cloned into the pGEM-T
Easy vector, conﬁrmed by sequencing and labeled with
32-P. Hybridization was performed in ExpressHyb
Hybridization Solution (BD Biosciences) at 608C.
Washing conditions were: 2 1min and 2 20min at
room temperature in 2 SSC; 0.1% SDS and 3 20min
at 608C in 0.5 SSC; 0.1% SDS. Quantiﬁcation of band
intensity was performed as for the genome-wide COBRA.
To calculate the percent of methylated CpGs, the percent
of sequences not carrying CpGs was deduced from the
non-digested band in the MspI digest.
Choice ofindividual LTRs
Individual LTRs were arbitrarily chosen as follows: the
consensus sequence of the three LTR-derived promoters
was derived by hand and placed upstream of the ﬁrst
1260bp of the HERV-E internal consensus sequence
termed ‘Harlequin’ by Repbase (25). This ﬁle was used
as a query to search the human genome for similar
sequences using the BLAT alignment tool (26). Among
the output sequences, LTRs were chosen based on the
following criteria: their total length had to match the
query and they had to be in the 50extremity of a provirus.
The genomic contexts also were taken into account: three
LTRs located in introns of genes expressed in placenta
were chosen (group B). Genes were considered to be
expressed in placenta if corresponding placental expressed
sequenced tag (ESTs) were reported in the UCSC Genome
Browser (27). Three LTRs were chosen to be the furthest
away from any known genes and EST-rich regions (group
C). Group A comprises the three LTR-derived promoters.
The percent identity between all LTRs analyzed here is
shown in Supplementary Table S3.
Determination of transcribed HERV-E copies in placenta
Human genome annotation data including retroelements,
ESTs and tissue information were obtained from the
UCSC annotation database (Mar. 2006 GenBank freeze,
hg18, Build 36.1). Because ESTs comprising only repeti-
tive/retroelement sequences (denoted as ‘simple ESTs’) are
not included in the UCSC annotation database, we also
retrieved the original sequences of those ESTs from NCBI
dbEST database (release version 154).
In the UCSC Genome Browser, some HERV-E
copies are annotated only by the disrupted fragments.
We computationally merged all the HERV-E fragments
into complete copies based on the following criteria: a
complete copy of HERV-E should have one of these
structures: LTR-internal-LTR, LTR-internal, internal-
LTR, LTR-only, internal-only. ‘LTR’ in the above
structures were sequences annotated as LTR2, LTR2B
or LTR2C; the ‘internal’ region annotated as either
‘HERVE’ or ‘Harlequin’; and all the merged fragments
should be on the same chromosome, in the same
orientation and with a distance of less than 10kb between
any two of them.
To determine which HERV-E copies are transcribed in
placenta, we used two diﬀerent strategies to deal with
the EST data from the UCSC annotation database
and the NCBI dbEST database, respectively. In the ﬁrst
case, the genomic coordinates of both HERV-Es and
ESTs from placenta are known, and by comparing these
coordinates, we identiﬁed all those HERV-Es which
overlapped with ESTs in placenta and assigned them as
speciﬁc HERV-E copies expressed in placenta. In the
second case, there was no information on genomic
coordinates available for those ‘simple ESTs’ from
NCBI. However, since HERV-E copies are relatively old
and diverged from other copies (e.g. Table S3), we
successfully mapped most of these ESTs to the human
genome with signiﬁcant mapping results by using BLAT
(standalone version: v. 33) (26). In order to reduce the
computational workload, we did not try to map all ‘simple
ESTs’ to the human genome, but only those derived from
HERV-Es by repeat-masking them with the HERV-E
consensus sequence and the CENSOR program (v 4.1)
downloaded from RepBase (28) After the mapping,
genomic coordinates of those ‘simple ESTs’ were
obtained, and the same strategy described in the ﬁrst
case was applied to ﬁnd speciﬁc HERV-E copies expres-
sing these ESTs in placenta.
Statistics
Distribution free Mann–Whitney U-tests and
Kruskal–Wallis H-tests were used for the statistical
analysis.
RESULTS AND DISCUSSION
Description ofthe three LTR-derived promoters studied
The three LTR-derived gene promoters analyzed here are
alternative promoters speciﬁcally active in placenta,
keeping the coding sequences of the genes intact, and
they are all derived from 50 LTRs of HERV-E proviruses
(29) (Figure 1).
The ﬁrst is the LTR-derived promoter of Pleiotrophin
(LTR-PTN) (30), a secreted heparin-binding cytokine
with diverse functions involving mitogenic activity in
ﬁbroblasts, endothelial and epithelial cells, lineage-speciﬁc
diﬀerentiation of glial progenitor cells, neurite outgrowth
and angiogenesis (31). A promoter of genomic origin
Nucleic Acids Research, 2007, Vol. 35, No. 14 4745called hereinafter ‘native promoter’ drives expression in
developing brain and in the adult testis, uterus, glia and
neurons. The provirus providing the LTR-PTN promoter
is located around 70kb downstream of the native
promoter and 7kb upstream of the ﬁrst coding exon.
Although Schulte et al. (30) reported that the LTR-PTN
was the only promoter responsible for placental expres-
sion, native-promoter driven transcripts in placenta are
present in Genbank. Experiments with PTN-depleted
choriocarcinoma cells suggest that placental expression
of PTN might be important for trophoblast growth,
invasion and angiogenesis in vivo.
The second LTR-derived gene promoter studied here is
associated with the endothelin B receptor gene (LTR-
EBR) (32). EBR is a G protein-coupled receptor of
endothelin (33). In human placenta, endothelins are
involved in fetoplacental circulation and can also act as
growth factors (34,35). The HERV-E provirus providing
the alternative promoter is located 57.5kb upstream of the
native promoter which has a ubiquitous expression
pattern. The LTR-EBR is responsible for about 15% of
the total amount of placental transcripts (36).
The last HERV-E LTR-derived promoter is linked to
the Midline 1 gene (LTR-MID1) (37). MID1 encodes a
microtubule-associated protein (38). Mutations in this
gene are involved in the pathogenesis of Opitz syndrome,
a genetic disorder aﬀecting midline structures (39).
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Figure 2. Methylation of HERV-E LTR-derived gene promoters.
Each line corresponds to a unique sequence of an LTR. Black circles
correspond to methylated CpGs and white circles to unmethylated
CpGs. Homologous CpGs between LTRs are connected by dashed
lines. White and black triangles indicate unmethylated and methylated
CpG sites, respectively, revealed by COBRA. Black and white triangles
present at the same CpG site indicate that the population of ampliﬁed
sequences contained both methylated and unmethylated CpGs at
this site. In this case, the triangle’s relative size corresponds to the
relative band intensity of the digested and undigested forms.
Connectors indicate CpG sites that were assayed by the same restriction
enzyme in COBRA (see Materials and Methods section). Crosses
correspond to mutated CpG sites. The number of methylated CpGs out
of the total CpG sites is reported for each LTR. Numbers 24, 25, etc.
on the left of each sequence indicate the corresponding placenta sample
(P24, P25, etc).
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Figure 1. Genomic context and organization of the HERV-E LTR-
derived gene promoters. Grey boxes correspond to HERV-E sequences;
grey arrows indicate HERV-E LTRs. White boxes represent gene
exons. The diﬀerent transcripts and their tissue speciﬁcity are shown. In
each case, the use of diﬀerent promoters does not aﬀect the open
reading frame.
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being widely expressed, one adipose tissue speciﬁc and the
LTR-MID1 placental and fetal kidney speciﬁc (40).
The provirus driving placental expression is located
between two ubiquitous promoters: at 13kb from the
downstream promoter and 30kb from the upstream
promoter (37). The retroviral promoter drives 25% of
the placental transcripts and 22% of the fetal kidney
transcripts (40).
Methylation statusof theHERV-E LTR-derived gene
promoters isin accordance withtheir expression profile
As mentioned earlier, LTR-MID1, LTR-EBR and LTR-
PTN are alternative promoters speciﬁcally expressed in
placenta (30,32,40). To assess whether their expression
correlates with their methylation levels, methylation of the
three LTRs was determined by COBRA and bisulﬁte
sequencing in placenta and PBL samples. Prior to this
analysis, the expression proﬁle of the three LTR-derived
promoters was conﬁrmed by RT-PCR in both tissues
using the same samples as for the methylation analysis. All
three promoters are active in placenta and silent in PBL
(data not shown). The results of the COBRA and the
bisulﬁte sequencing in placenta and PBL are shown in
Figure 2. In placenta, these three LTRs are almost
completely unmethylated. In contrast, they are heavily
methylated in PBL. The results obtained by COBRA are
in good agreement with those obtained by bisulﬁte
sequencing demonstrating that the sequenced clones are
representative of the pool of ampliﬁed sequences. The low
methylation of all three LTR-derived promoters in
placenta and their high degree of methylation in PBL
indicates that methylation and expression proﬁles of the
HERV-E LTR-derived promoters correlate. These results
suggest that DNA methylation is involved in regulation of
the three LTR-derived gene promoters.
HERVs in placentaare onlyslightly less methylated
thanin PBL
To clearly address the question of whether the strong
hypomethylation of LTR-derived promoters in placenta
reﬂects an overall hypomethylation of HERVs in this
tissue, a Southern blot analysis with methylation-sensitive
enzymes was attempted. However, use of a HERV-E
speciﬁc probe resulted in smears and lack of any deﬁned
bands (data not shown). This is presumably due to the
relatively high divergence (10–30%) between HERV-E
copies. Since HERV-Es are too divergent for Southern
blot analysis, a genome-wide COBRA analysis was
performed. For this, primers corresponding to relatively
conserved regions of the consensus LTR2B—a subfamily
of HERV-E LTRs— were chosen allowing the ampliﬁca-
tion of 78 copies, as predicted by the UCSC In-silico PCR
program (UCSC Genome Browser). Out of the 78 copies,
54% have a SnaBI restriction site and 46% a ClaI site,
both sites including a CpG dinucleotide. A DraI site
(TTTAAA) present on all 78 sequences was used to
control that, when methylation is not a factor, the
digestion proﬁle was as expected according to the
in silico predictions and was identical for both samples
from placenta and PBL. COBRA of this heterogeneous
amplicon (Figure 3A) yields a double band of lower size
(bands number 2; Figure 3A) corresponding to the
methylated sequences. The undigested band (band 1;
Figure 3A) corresponds to LTR copies with either
unmethylated CpG sites or those not containing the
CpG site. Measurement of the relative intensity of bands 1
and 2 for each of the digestions of three independent
experiments with SnaBI and one with ClaI shows 4–25%
lower methylation in placenta compared to PBL. The
average of the diﬀerent measures suggests 14% lower
methylation of HERV-E in placenta than in PBL.
However, to correctly calculate these percentages, the
precise proportion of sequences lacking the tested CpG
sites is necessary. With this method, this proportion is
theoretical, based on the prediction of the In-silico PCR
program. This prediction could be somehow biased, since
the primers used in silico correspond to non-bisulﬁte
treated DNA and are diﬀerent from the actual primers
used in the COBRA. The experimental estimation of the
proportion of the actual CpG lacking sequences in the
pool of ampliﬁed sequences is impossible. Hence, another
experimental procedure allowing a more accurate estima-
tion of the percent of methylation was necessary, in order
to conﬁrm our results obtained by the genome-wide
COBRA.
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uncut DraI SnaBI ClaI
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*
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gag 5′ LTR
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C
Figure 3. Methylation of HERV-E and HERV-K sequences in placenta
and PBL. (A) Genome-wide COBRA on HERV-E LTRs. Bisulﬁte
treated DNA from placenta (P lanes) and PBL (B lanes) were used as
template for PCR with primers amplifying HERV-E LTRs. PCR
amplicons were treated with three restriction enzymes (SnaBI, ClaI and
DraI). Bands 2 for SnaBI and ClaI digests correspond to sequences
with methylated CpGs, whereas band 1 to a mix of sequences with
unmethylated CpGs and sequences lacking the CpG site. The CpG free
DraI restriction site is present in all sequences and was used as a
control (see text). (B) and (C) methylation of HERV-K family
determined by Southern blot. (B) Schematic representation of HERV-
K5 0 LTR and gag region, with the restriction sites of the enzymes used.
The bar with the asterisk corresponds to the probe overlapping the gag
region. (C) Autoradiogram of the Southern blot. Lanes B are loaded
with genomic DNA from PBL and lanes P with genomic DNA from
placenta. Bands labeled 1 and 2 correspond to restriction fragments
1 and 2 shown in B.
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HERV-K [HML-2 subfamily, 1–2% divergence (41)], was
chosen to carry out a Southern blot with methylation
sensitive enzymes. MspI and its methylation-sensitive
isoschizomer HpaII were used and the results are
shown in Figure 3B and C. The majority of HERV-K
copies seem to be methylated at the tested CpG site in
the LTR both in placenta and PBL. Measurement of
the relative intensity of bands 1 and 2 from two
independent experiments and diﬀerent exposure times,
suggests 9–14% less methylation of HERV-K in placenta
than in PBL with an average of 11%. This percentage is
very similar to the one obtained by the genome-wide
COBRA on HERV-E sequences.
Taken together, these results show a slightly lower
methylation of two families of HERVs in placenta
than in PBL. This observation could reﬂect a general
phenomenon of HERV families. Moreover, our results
are in accordance with the previous results mentioned
earlier that found general placental hypomethylation
of 10–27% compared to other tissues. However, the
LTR-derived promoters are about 80% less methylated in
placenta than in PBL indicating that these particular
copies are not representative of the bulk of HERV-E
copies regarding their methylation levels in the tissues
tested.
Comparison of methylation levels between HERV-E LTRs
in differentgenomic contexts
To compare the methylation levels of other HERV-E
copies inserted in similar or diﬀerent genomic contexts
with those of the LTR-derived promoters, we chose six
HERV-E proviruses without any known gene-promoting
function (see Materials and Methods section) and the
methylation of their 50 LTRs in placenta was determined
by both COBRA and bisulﬁte sequencing. We deﬁne
‘group A’ as the three LTR-derived gene promoters
described previously and ‘group B’ as the three out of
the six random LTRs located in introns of genes expressed
in placenta (Figure 4). LTRs of groups A and B have
similar genomic context: they are all located in introns
of genes expressed in placenta with the exception of LTR-
EBR which is located 57.7kb upstream of the ﬁrst exon of
EBR gene (Figure 1). LTR-VI is located in an intron of
the Ankyrin S1 (ANKS1) gene expressed in many tissues
including placenta. LTR-II is located in an intron of the
Tissue Factor Pathway Inhibitor 1 gene (TFPI1) expressed
mainly in endothelial cells and also in placenta. LTR-IV-2
is located in an intron of the TMEM144 gene highly
expressed in the central nervous system and providing a
few ESTs in placenta. The other three LTRs are located
far away from any annotated gene and are ‘group C’
~105 kb from promoter
13 kb
8 9
ANKS1
LTR-VI
4 kb
~37 kb 6 kb
12
TFPI1
LTR-II
~43 kb from promoter
67 LTR-IV-2
4 kb 3 kb
~21 kb from promoter
TMEM144
brain
placenta
endothelial
cells,
placenta
ubiquitous
LTRs of group B LTRs of group C
LTR-IV PCDH7 CENTD1
4.5 Mb 980 kb
MGC48628 GRID2 LTR-IV-3
1.3 Mb 260 kb
LTR-III SI C3orf57 
2.7 Mb 570 kb
Figure 4. Genomic context and organization of the HERV-E LTRs of groups B and C. Grey boxes correspond to HERV-E sequences; grey arrows
indicate HERV-E LTRs. White boxes with solid lines represent gene exons and white boxes with dashed halves represent genes. LTRs of group B
located in introns of genes expressed in placenta and other tissues. ANKS1: Ankyrin repeat and SAM domain—containing protein 1; TFP1: tissue
factor pathway inhibitor; PCDH7: protocadherin 7 isoform c precursor; CENTD1: centaurin delta 1 isoform b; GRID2: glutamate receptor,
ionotropic, delta 2; SI: sucrase-isomaltase (alpha-glucosidase); TMEM144: transmembrane protein 144.
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LTRs are shown in Figure 5. LTRs of group B present
22.6–41.2% methylation and LTRs of group C 30.5–91%
methylation. COBRA results are in good accordance with
bisulﬁte sequencing results reﬂecting the global methyla-
tion of each LTR. Group A and B LTRs have no
signiﬁcant intra-group diﬀerences in their methylation
levels in placenta whereas group C is very heterogeneous
in terms of methylation. Hence, it cannot be considered as
a homogeneous group regarding methylation. This could
be due to the fact that the deﬁnition of this group as
‘far from genes’ is inexact: the presence of unknown genes
or transcriptional activity in the vicinity of such LTRs
cannot be excluded. For instance, LTR-III shows a
methylation level (30.5%) similar to the levels displayed
by LTRs of the group B. LTR-III could be located nearby
an un-annotated transcriptionally active region. However,
according to the UCSC Genome Browser, no obvious
diﬀerence is observed between the insertion sites of group
C LTRs with regard to EST occurrence in nearby regions
or the conservation of the surrounding sequences between
mammalian species. The other two LTRs of group C,
LTR-IV and LTR-IV-3, have signiﬁcantly higher methy-
lation levels when compared to group B and group A
(Figure 6). The comparison between groups A and B, both
located in introns of genes expressed in placenta, shows
that group A displays highly signiﬁcant lower methylation
than group B (P=2e
 06). This shows that groups A and
B, although located in regions with similar transcriptional
activity, diﬀer in their methylation status. In conclusion,
LTR-derived promoters have signiﬁcantly lower methyla-
tion levels than any arbitrarily chosen LTR even when
located in similar genomic contexts.
Identification of HERV-E copies transcribed inplacenta
Our study shows that HERV-E copies display widely
variable methylation levels in placenta. It was unknown
how many of the approximately 294 copies of the
full-length HERV-E proviruses [out of  1200 total
HERV-E copies (42)] are transcriptionally active in
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each LTR-derived promoter of group A, in order to align the
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data on methylation of group A LTRs). Panels (B) and (C) show the
methylation status of the LTRs belonging to groups B and C as
described in the text.
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similarity and location criteria but with no knowledge of
their expression status. To gain an estimate of the number
of HERV-E copies transcribed in placenta and to assess
whether the diﬀerence of methylation between copies
correlates with expression, we extracted placental ESTs
homologous to HERV-E derived sequence and then
identiﬁed the speciﬁc copies of HERV-Es producing
each of these ESTs (see Materials and Methods section).
The results are shown in Table 1. The 162 placenta-speciﬁc
ESTs were clearly identiﬁed as corresponding to HERV-E
sequences but only 74 could be unambiguously mapped to
26 HERV-E loci. ESTs comprising only HERV-E
sequences are described as ‘simple’ and those comprising
non-HERV-E sequences as well are denoted as ‘chimeric’.
ESTs starting inside the 50LTR are likely to correspond to
transcripts initiated by the LTR itself. Only 10 of the
26 copies are associated with this type of EST and are
classiﬁed as ‘likely’ transcriptionally active copies. Among
these, the proviruses corresponding to the three LTR-
derived promoters were identiﬁed. ESTs corresponding to
HERV-E’s internal region could be the result of tran-
scription initiated by the provirus itself or by upstream
sequences. Therefore nine copies associated with these
types of placental ESTs are classiﬁed as ‘possibly’
transcriptionally active. Among these copies, LTR-II
and LTR-VI were identiﬁed, both members of group B.
ESTs comprising the upstream ﬂanking sequence of a
50LTR or corresponding to copies deleted in their 50
extremity are probably transcribed from a genomic
promoter upstream of the provirus. Consequently, they
are considered as ‘unlikely’ transcriptionally active copies.
LTR-II provides ﬁve ESTs corresponding only to its
internal sequence and four spliced ESTs composed of
exons corresponding to the provirus and the ﬂanking
gene. Hence the LTR-II copy is considered as possibly
active but also involved in read-through transcription.
Interestingly, one of the ‘likely’ active copies (chromosome
1:166098952–166105765) seems to act as an alternative
promoter for the IQWD1 gene of unknown function.
Therefore, over one third of the ‘likely’ transcriptionally
active copies correspond to LTR-derived alternative gene
promoters.
As reported by others (43), this study suggests that
only a limited number of HERV-E loci are transcrip-
tionally active. Notably, only two out of the 1200
HERV-E copies present in the genome, those at chromo-
some 17: 23581671–23590492 and chromosome 20:
24847861–24861663, provide 36% of the HERV-E pla-
cental ESTs (Table 1). Moreover, solitary LTRs represent
75% of all HERV-E copies but only 16% of the ‘likely’ or
‘possibly’ active copies correspond to this type of element.
It seems that full length copies are more expressed than
solitary LTRs as previously observed (43). It is also
Table 1. HERV-E copies providing ESTs in placenta
HERV-E Chromosome:
coordinates
Strand Simple
ESTs
Chimeric
ESTs
Total
ESTs
Comments
Likely Solo LTR 1: 89420430–89421200   01 1
Full length 1: 166098952–166105765 + 1 2 3 Alternative promoter of IQWD1
30 deleted 2: 34755763–34756702 + 0 1 1
Solo LTR 2: 96948142–96948605 + 0 1 1
Full length 7: 136597798–136604133   03 3 LTR-PTN
Full length 13: 77442456–77448210   03 3 LTR-EBR
 Full length 19: 58093589–58099917   20 2
Full length 21: 43225142–43230724 + 2 0 2
Solo LTR X: 3863806–3864286 + 1 0 1
Full length X: 10512832–10518380   32 5 LTR-MID1
Possibly Full length 1: 204449081–204455474   20 2
  Full length 2: 188083461–188090051 + 5 0 5 LTR-II
Full length 6: 35074115–35080062 + 2 0 2 LTR-VI
Full length 6: 111712066–111718525   10 1
Full length 10: 73369141–73376272 + 2 0 2
Full length 17: 23581671–23590492   11 0 11
Full length 17: 38565788–38573241   10 1
30 deleted 19: 63018482–63019644 + 1 0 1
Full length 20: 24847861–24861663 + 9 0 9
Unlikely Full length 1: 1337494–1344095   0 2 2 Genomic+50LTR
  Full length 2: 188083461–188090051 + 0 4 4 LTR-II internal region spliced
into gene exons
Internal sequence 10: 15072826–15076892   0 1 1 Flanking+internal sequence
50 deleted 11: 3451334–3459517   0 2 2 Internal sequence+ﬂanking
Internal sequence 13: 44848741–44856042   0 3 3 HERVE duplications – gene exons
Solo LTR 16: 29617072–29617563 + 1 2 3 Flanking+LTR
 Full length 19: 58093589–58099917   0 1 1 Flanking+50LTR
Solo LTR 19: 60156353–60156881   0 1 1 Flanking+50LTR, alternative
prom NALP2
Internal sequence 21: 43236635–43249084   1 0 1 Internal sequence
  and
   are proviruses that appear in two diﬀerent categories because they provide two types of ESTs.
4750 Nucleic Acids Research, 2007, Vol. 35, No. 14surprising that two LTRs (II and VI) out of the 294 full
length copies identiﬁed in this screening as possibly active
happened to be chosen at random for our methylation
study of individual LTRs. This is very likely due to
the criteria used for the choice of the individual LTRs: the
sequence similarity to the LTR promoters (LTR-VI is the
closest related to the LTRs MID-1 and PTN and LTR-II
to LTR-EBR, see Table S3), the fact that they are part of
full length proviruses and their localization in introns of
genes expressed in placenta. All these criteria seem to
increase the likelihood for an LTR to be active in
placenta.
We attempted to determine whether a clear relation
existed between level of methylation and level of expres-
sion as reﬂected by the number of ESTs found in placenta.
Among the copies studied here, only ESTs corresponding
to unmethylated copies (group A) or to copies with
intermediary levels of methylation (group B) were found.
Although these two groups diﬀer by their methylation
levels, no obvious diﬀerence was observed in the number
of ESTs that they provide and the amount of data does
not allow any statistical analysis. Therefore, experimental
analysis of their expression is necessary to determine
if diﬀerences in methylation levels as low as 20% aﬀect
expression. It has been reported that the same
Intracisternal-A-Particle (IAP)-LTR promoter can be
active or silenced in diﬀerent individual mice when its
methylation diﬀers only by 20–30% (44). This could be
due to the fact that, in some cases, LTR promoters seem
to be active not because of their overall hypomethylation
in a given tissue but because of their complete demethyla-
tion in a limited number of cells of this tissue. Indeed, the
IAP-LTRs mentioned above, show not only a strong
variability in methylation between mice but also a mosaic
methylation between cells of the same mouse. A similar
phenomenon could explain why our study identiﬁed ESTs
corresponding to LTR-VI and LTR-II but not LTR-IV-2.
The latter is the only one from group B not presenting
any completely demethylated sequences. In addition,
when diﬀerent LTRs are compared, it is very likely that
methylation or chromatin context is not the only factor
responsible for the transcription levels; sequence diver-
gence and heterogeneity for transcription factor binding
sites will be involved as well (17). For example, when the
promoter activity of two unmethylated HERV-K LTRs
was compared in transient transfection assays, they
displayed diﬀerent levels of transcription (4). However,
when their endogenous expression was tested in human
teratocarcinoma cells, they displayed diﬀerent levels of
transcription but in the opposite sense, since the stronger
LTR promoter is more methylated in the cell.
Comparison of methylation levels between LTRs andtheir
flankingsequences
To determine if methylation of HERV-E LTRs is the same
as their ﬂanking sequence and if the diﬀerence in
methylation between LTR-derived promoters (group A)
and random LTRs located in similar genomic contexts
(group B) is related to diﬀerences in methylation of
their ﬂanking regions, we determined the methylation
status of ﬂanking sequences of two LTRs from group A
(LTR-MID1 and LTR-EBR), one LTR from group B
(LTR-IV-2) and one LTR of group C (LTR-IV).
Methylation of the CpG sites contained in 500bp adjacent
to the LTRs was determined by bisulﬁte sequencing and
results are shown in Figure 7. LTR-IV (group C) has the
same methylation level as its ﬂanking sequence, whereas
LTR-IV-2 (group B) and LTR-MID1 have much lower
methylation levels compared to their ﬂanking sequence
(P50.001, Figure 7). For LTR-EBR and its ﬂanking
sequence, no signiﬁcant diﬀerence in methylation level
was revealed by bisulﬁte sequencing. However, a COBRA
of LTR-EBR and its ﬂanking region suggests a low
methylation level of the ﬂanking sequence and a
complete absence of methylation for the LTR-EBR
itself. The ﬂanking sequences of LTR-IV-2 and LTR-
MID1 show similar, high methylation levels (92.3% and
70.4%, respectively) even though they are located in
introns of genes expressed in placenta. This discrepancy
between levels of methylation of the LTRs and their
ﬂanking sequences is striking since it is believed that
the main determinant of ERV methylation is the
chromatin state of their insertion site (10). To conﬁrm
this pattern and eliminate the possibility that this
observation results from eventual PCR biases, we
ampliﬁed and sequenced 500bp containing ﬁve CpGs of
the LTR-IV-2 and three CpGs of its ﬂanking sequence
(Figure 7). Indeed, these clones conﬁrm the pattern
observed previously. For LTR-IV-2, methylation from
the ﬂanking sequence seems to spread over the ﬁrst CpGs
of the LTR but drops gradually towards the internal CpG
sites. Methylation of LTR-MID1 seems to drop more
abruptly at the border of its 50 extremity resulting in
a clear-cut diﬀerence of the methylation level between
LTR-MID1 and its ﬂanking sequence. This diﬀerence
between LTR-IV-2 and LTR-MID1 could be explained by
a less eﬃcient spreading of methylation through LTR-
MID1 because of a lower density of CpGs in the ﬂanking
sequence or/and to transcription factors binding to the
LTR and protecting it from methylation (45,46). Indeed,
LTR-MID1 is transcriptionally active, but no ESTs
corresponding to LTR-IV-2 were identiﬁed by our screen-
ing of the NCBI database, suggesting this LTR is not
active. Moreover, no diﬀerence in methylation between
ﬂanking sequences of diﬀerent groups was observed: they
all present high methylation levels except for one of the
two members of group A (LTR-EBR). Considering CpG
sites located in other repeats present in the ﬂanking
sequences, there is no evidence for more methylation
of repeated DNA compared to unique sequences.
In conclusion, very diﬀerent levels of methylation are
observed in ﬂanking sequences, an observation that
cannot be explained by the nature of the sequence
(repeat or unique) or the transcriptional activity (intron
or inter-genomic sequence). Our results suggest that
there is no systematic correlation between methylation
levels of HERV-E LTRs and their ﬂanking sequences.
Furthermore, the hypomethylation of the LTR-derived
promoters compared to random LTRs cannot be
explained by a diﬀerence in methylation of their ﬂanking
sequences.
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In this study, we report methylation levels of nine
HERV-E LTRs. We show that methylation levels of
LTRs in placenta are widely variable, ranging from 4% to
91%. It seems that the genomic environment has an
impact on the methylation level of the LTRs, since those
located in well-deﬁned genomic environments such as
introns of genes expressed in placenta (groups A and B)
have similar levels of methylation in intra-group compar-
isons. However, genomic environment alone cannot
explain other diﬀerences observed; for example, the
diﬀerence between LTR-derived promoters and LTRs
located in introns of genes expressed in placenta. This
statement is even clearer when ﬂanking sequences of LTRs
are compared. The methylation level of an LTR is not
systematically similar to that of its ﬂanking
sequence, whether it is an LTR-derived promoter or a
random LTR. Clearly, spreading of heterochromatin is
not the only determinant of the degree of methylation of
LTR promoters. Other factors such as transcription
factors binding the LTRs are likely involved. Expression
levels of individual LTRs will depend on both methyla-
tion/chromatin context as well as the retention of
transcription factor binding sites. Indeed, our in silico
screening for transcriptionally active HERV-Es in pla-
centa show that very few of them are active, very likely
because expression is dependent on the combination of
factors mentioned earlier.
LTR-derived promoters occur more frequently in
placenta than in any other tissue (23,24). This does not
seem to be solely due to a general hypomethylation
of the DNA in this tissue, since the LTR-derived
promoters studied here are almost completely unmethy-
lated and therefore do not reﬂect general methylation
levels. Moreover, LTR-MID1 is located in a highly
methylated ﬂanking region showing that its lack of
methylation does not result from a general ‘protection’
of the surrounding sequence against methylation.
5′ flanking LTR-IV 
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71/78   91%
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19/27  70.4%
LTR-MID1  (group A) 
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LTR-IV-2  (group B)
45/154  29.2% 
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24/26  92.3%
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5′ flanking LTR-EBR
2/12   16.7%
Figure 7. Methylation levels of HERV-E LTRs and their ﬂanking sequences. Grey arrows correspond to HERV-E LTRs, with their ﬂanking
sequence represented on the left by a line for unique genomic sequences or by a box for repeated sequences. The dashed box represents an Alu
element, the white box with black dots an L1 and the black box with the white dots an L2 element. The orientation of the repeats is shown by
arrows. The methylation of each region is shown below by lines corresponding to the sequence of a single clone. Other symbols are as in Figure 2.
4752 Nucleic Acids Research, 2007, Vol. 35, No. 14Consequently, the expression of LTR-derived promoters
in placenta cannot be explained only as a secondary eﬀect
of the genomic environment. The HERV-E LTR-derived
gene promoters studied here present tissue-speciﬁc methy-
lation in accordance with their expression proﬁle. Their
epigenetic status and activity make them more analogous
to tissue-speciﬁc promoters of genomic origin than to
transposable elements.
Overwhelming evidence for essential roles of ERV-
encoded proteins in placenta morphogenesis and evolu-
tion has been reported in recent years (47–49). However,
there may be additional impact of ERVs in the placenta
due to host gene regulation eﬀects. It is clear that most
genes essential for placental development are not speciﬁc
for this tissue (50), suggesting that placenta speciﬁc
regulatory networks may play an important role in
morphogenesis and evolution of this organ.
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